CN112469442B - 用于治疗肾脏疾患的化合物 - Google Patents

用于治疗肾脏疾患的化合物 Download PDF

Info

Publication number
CN112469442B
CN112469442B CN201980048869.4A CN201980048869A CN112469442B CN 112469442 B CN112469442 B CN 112469442B CN 201980048869 A CN201980048869 A CN 201980048869A CN 112469442 B CN112469442 B CN 112469442B
Authority
CN
China
Prior art keywords
compound
compound according
cpd
compounds
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980048869.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN112469442A (zh
Inventor
阿尔西亚·弗农尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to CN202311697211.0A priority Critical patent/CN117736141A/zh
Publication of CN112469442A publication Critical patent/CN112469442A/zh
Application granted granted Critical
Publication of CN112469442B publication Critical patent/CN112469442B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980048869.4A 2018-07-26 2019-07-26 用于治疗肾脏疾患的化合物 Active CN112469442B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311697211.0A CN117736141A (zh) 2018-07-26 2019-07-26 用于治疗肾脏疾患的化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18185871.3 2018-07-26
EP18185871 2018-07-26
PCT/EP2019/070251 WO2020021097A1 (en) 2018-07-26 2019-07-26 Compounds for use in treating kidney disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311697211.0A Division CN117736141A (zh) 2018-07-26 2019-07-26 用于治疗肾脏疾患的化合物

Publications (2)

Publication Number Publication Date
CN112469442A CN112469442A (zh) 2021-03-09
CN112469442B true CN112469442B (zh) 2024-04-09

Family

ID=63077813

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980048869.4A Active CN112469442B (zh) 2018-07-26 2019-07-26 用于治疗肾脏疾患的化合物
CN202311697211.0A Pending CN117736141A (zh) 2018-07-26 2019-07-26 用于治疗肾脏疾患的化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311697211.0A Pending CN117736141A (zh) 2018-07-26 2019-07-26 用于治疗肾脏疾患的化合物

Country Status (13)

Country Link
US (3) US20200085810A1 (enExample)
EP (2) EP4537901A3 (enExample)
JP (2) JP7478133B2 (enExample)
KR (1) KR102860768B1 (enExample)
CN (2) CN112469442B (enExample)
AU (1) AU2019310919B2 (enExample)
CA (1) CA3104793A1 (enExample)
ES (1) ES3005632T3 (enExample)
IL (1) IL280368B2 (enExample)
MX (1) MX2021000976A (enExample)
PL (1) PL3826679T3 (enExample)
TW (1) TWI891608B (enExample)
WO (1) WO2020021097A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085810A1 (en) * 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
WO2022006277A1 (en) * 2020-07-01 2022-01-06 Angion Biomedica Corp. Methods for treatment of fibrotic kidney diseases
US11814354B2 (en) 2021-09-08 2023-11-14 River 3 Renal Corp. Solid forms

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103442712A (zh) * 2011-01-26 2013-12-11 赛诺菲 取代的3-杂芳酰基氨基-丙酸衍生物及其作为药物的用途
CN103608332A (zh) * 2011-06-10 2014-02-26 霍夫曼-拉罗奇有限公司 可用作cb2激动剂的吡啶-2-酰胺类
WO2014180741A1 (en) * 2013-05-06 2014-11-13 F. Hoffmann-La Roche Ag Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1270846B (it) 1993-05-10 1997-05-13 Alfa Wassermann Spa Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica.
US7030146B2 (en) 1996-09-10 2006-04-18 University Of South Carolina Methods for treating diabetic neuropathy
MXPA06010815A (es) 2004-03-26 2006-12-15 Hoffmann La Roche Tetrahidrocarbazoles y derivados de los mismos.
EP1756096B1 (en) 2004-05-03 2009-08-12 F.Hoffmann-La Roche Ag Indolyl derivatives as liver-x-receptor modulators
UA107088C2 (xx) * 2009-09-11 2014-11-25 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину
AR079022A1 (es) * 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
WO2012031817A1 (en) 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
BR112014005634A2 (pt) 2011-09-12 2017-03-28 Hoffmann La Roche hidrazidas de 3-piridina ácido carboxílico como agentes de aumento de colesterol hdl
KR20160030206A (ko) * 2013-07-10 2016-03-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 사구체 질환을 치료하는데 사용하기 위한 로스마피모드
US20200085810A1 (en) * 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103442712A (zh) * 2011-01-26 2013-12-11 赛诺菲 取代的3-杂芳酰基氨基-丙酸衍生物及其作为药物的用途
CN103608332A (zh) * 2011-06-10 2014-02-26 霍夫曼-拉罗奇有限公司 可用作cb2激动剂的吡啶-2-酰胺类
WO2014180741A1 (en) * 2013-05-06 2014-11-13 F. Hoffmann-La Roche Ag Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ApoAI/ABCA1途径对糖尿病肾病大鼠的保护作用;李彤等;《深圳中西医结合杂志》;20150909;第25卷(第17期);第1-3页 *
Tangshen Formula Attenuates Diabetic Nephropathy by Promoting ABCA1-Mediated Renal Cholesterol Efflux in db/db Mice;Peng Liu等;《Frontiers in Physiology》;20180430;第9卷;第1-11页 *
杜春阳等.高糖对肾小管细胞胆固醇转运的影响及花青素的干预研究.《中国药理学通报》.2015,第32卷(第1期), *
高糖对肾小管细胞胆固醇转运的影响及花青素的干预研究;杜春阳等;《中国药理学通报》;20151223;第32卷(第1期);第117页右栏第2段 *

Also Published As

Publication number Publication date
PL3826679T3 (pl) 2025-03-10
JP7478133B2 (ja) 2024-05-02
KR20210038884A (ko) 2021-04-08
AU2019310919B2 (en) 2025-04-03
IL280368B1 (en) 2023-10-01
CA3104793A1 (en) 2020-01-30
JP2024096989A (ja) 2024-07-17
EP3826679B1 (en) 2024-11-27
EP4537901A2 (en) 2025-04-16
US20240325372A1 (en) 2024-10-03
TW202019486A (zh) 2020-06-01
JP2021531308A (ja) 2021-11-18
KR102860768B1 (ko) 2025-09-17
EP4537901A3 (en) 2025-05-21
AU2019310919A1 (en) 2021-01-07
US20200085810A1 (en) 2020-03-19
TWI891608B (zh) 2025-08-01
WO2020021097A1 (en) 2020-01-30
IL280368A (en) 2021-03-25
ES3005632T3 (en) 2025-03-14
US20210275514A1 (en) 2021-09-09
IL280368B2 (en) 2024-02-01
EP3826679C0 (en) 2024-11-27
EP3826679A1 (en) 2021-06-02
CN112469442A (zh) 2021-03-09
CN117736141A (zh) 2024-03-22
MX2021000976A (es) 2021-03-31

Similar Documents

Publication Publication Date Title
US20240325372A1 (en) Compounds for use in treating kidney disorders
JP5770950B2 (ja) アポトーシスシグナル調節キナーゼ阻害剤
Ninou et al. Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis
EP2651403B1 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
US20220280484A1 (en) Novel use
JP2014523881A (ja) プロテイノパチーの処置方法
WO2019173482A1 (en) 4-aminoquinoline compounds for the treatment of angiogenesis
Shi et al. Losartan attenuates scar formation in filtering bleb after trabeculectomy
CA3168728A1 (en) Compositions and methods for treating renal injury
Pozzi et al. Olanzapine, risperidone and ziprasidone differently affect lysosomal function and autophagy, reflecting their different metabolic risk in patients
KR20080064911A (ko) 선택적 노르아드레날린 재흡수 억제제와 ｐｄｅｖ 억제제의조합물
US20240279201A1 (en) Dual wnt signaling pathway inhibitors and ampk activators for treatments of disease
US9403755B2 (en) Isometheptene isomer
HK40040900A (en) Compounds for use in treating kidney disorders
HK40102350A (zh) 用於治疗肾脏疾患的化合物
HK40040900B (zh) 用於治疗肾脏疾患的化合物
CN112384497A (zh) 具有选择性nox抑制活性的新型磺酰胺衍生物
CN110418641A (zh) 用于组合疗法的药物组合物
WO2023199010A1 (en) Treatment of muscle fibrosis
CA2868785A1 (en) Compositions and methods for inhibiting drusen
JP2003321393A (ja) Ｆｙｎ阻害剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40040900

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant